Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.’s (NASDAQ: SRPT ) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) into traditional approvals for Duchenne muscular dystrophy (DMD). • Sarepta T